JAZZ vs. MTD: Jazz Pharmaceuticals vs. Mettler-Toledo Stock Comparison
How do Jazz Pharmaceuticals (JAZZ) and Mettler-Toledo (MTD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Jazz Pharmaceuticals (JAZZ) and Mettler-Toledo (MTD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but JAZZ is classified in Pharmaceuticals while MTD is classified in Life Sciences Tools & Services.
| Profile Item | JAZZ | MTD |
|---|---|---|
| Name | Jazz Pharmaceuticals plc | Mettler-Toledo International Inc. |
| Country/Region | Ireland | Switzerland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Life Sciences Tools & Services |
| GICS Sub-Industry | Pharmaceuticals | Life Sciences Tools & Services |
| Market Capitalization | 15.07 billion USD | 34.25 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | June 1, 2007 | November 14, 1997 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | JAZZ | MTD |
|---|---|---|
| Total Return (1Y) | 84.44% | 21.58% |
| Total Return (3Y, Annualized) | 27.57% | 19.54% |
| Total Return (5Y, Annualized) | 12.88% | 2.36% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | JAZZ | MTD |
|---|---|---|
| Volatility (1Y, Annualized) | 38.74% | 31.70% |
| Beta (5Y) | 0.33 | 1.15 |
| Max Drawdown (5Y) | -42.03% | -43.47% |
| Avg. Volume (3M) | 878.80K | 197.80K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | JAZZ | MTD |
|---|---|---|
| Sharpe Ratio (1Y) | 2.07 | 0.55 |
| Sortino Ratio (1Y) | 4.14 | 0.75 |
Profitability
ROE (TTM)
Capital efficiency shows on one side only: Jazz Pharmaceuticals (JAZZ) earns 5.05% on shareholders’ equity, ranked against its industry; Mettler-Toledo (MTD) has no ROE this period.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.05%
- Max
- 109.18%
- Q3
- 6.23%
- JAZZ
- 5.05%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- MTD
- --
Net Margin (TTM)
Mettler-Toledo (MTD) at 22.25% converts revenue to bottom-line profit above its industry’s benchmark range, while Jazz Pharmaceuticals (JAZZ) at 4.37% keeps roughly the typical share for its industry.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.37%
- Max
- 18.05%
- Q3
- 4.78%
- JAZZ
- 4.37%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.25%
- MTD
- 22.25%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Jazz Pharmaceuticals (JAZZ) at 30.17% and Mettler-Toledo (MTD) at 28.70% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.17%
- Max
- 83.12%
- JAZZ
- 30.17%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.70%
- Max
- 83.12%
- MTD
- 28.70%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | JAZZ | MTD |
|---|---|---|
| ROE (TTM) | 5.05% | -- |
| ROA (TTM) | 6.92% | 20.09% |
| Net Margin (TTM) | 4.37% | 22.25% |
| Operating Margin (TTM) | 30.17% | 28.70% |
| Gross Margin (TTM) | 91.10% | 59.16% |
Growth
Revenue Growth
Both Jazz Pharmaceuticals (JAZZ) at 4.88% and Mettler-Toledo (MTD) at 3.98% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Mettler-Toledo (MTD) at 3.88% is around its peer norm for EPS growth, while Jazz Pharmaceuticals (JAZZ) at -167.51% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | JAZZ | MTD |
|---|---|---|
| Revenue Growth (YoY) | 4.88% | 3.98% |
| Revenue Growth (3Y CAGR) | 5.26% | 0.90% |
| EPS Growth (YoY) | -167.51% | 3.88% |
| EPS Growth (3Y CAGR) | -- | 3.06% |
Financial Strength
Current Ratio (MRQ)
Both Jazz Pharmaceuticals (JAZZ) at 1.82 and Mettler-Toledo (MTD) at 1.10 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.82
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- JAZZ
- 1.82
- Min
- 0.10
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.10
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- MTD
- 1.10
- Min
- 0.10
Debt / Equity (MRQ)
Both balance sheets lean debt-heavy versus peers, but MTD is more stretched: Jazz Pharmaceuticals (JAZZ) at 1.35 sits in the higher-leverage quartile and Mettler-Toledo (MTD) at 26.06 is above its industry benchmark range.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 1.42
- JAZZ
- 1.35
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.06
- MTD
- 26.06
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | JAZZ | MTD |
|---|---|---|
| Current Ratio (MRQ) | 1.82 | 1.10 |
| Debt / Equity (MRQ) | 1.35 | 26.06 |
| Net Debt / EBITDA | 1.39 | 1.58 |
Dividends
Dividend Yield (TTM)
Neither Jazz Pharmaceuticals (JAZZ) nor Mettler-Toledo (MTD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MTD
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Jazz Pharmaceuticals (JAZZ) nor Mettler-Toledo (MTD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MTD
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | JAZZ | MTD |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Mettler-Toledo (MTD) at 37.38 is near its industry’s usual P/E ratio, while Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer quartile — JAZZ needs stronger growth or earnings quality to justify the premium.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
69.46
- Max
- 85.34
- JAZZ
- 69.46
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
37.38
- Max
- 85.34
- Q3
- 43.46
- MTD
- 37.38
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Jazz Pharmaceuticals (JAZZ) at 3.19 and Mettler-Toledo (MTD) at 8.16 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.19
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- JAZZ
- 3.19
- Q1
- 3.01
- Min
- 0.01
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.16
- Max
- 58.18
- Q3
- 25.77
- MTD
- 8.16
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Jazz Pharmaceuticals (JAZZ) at 3.59 sits near its industry’s typical P/B ratio, while Mettler-Toledo (MTD) at 442.71 prices above its benchmark range — MTD looks rich relative to book.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.59
- Max
- 13.53
- Q3
- 6.54
- JAZZ
- 3.59
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
442.71
- MTD
- 442.71
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | JAZZ | MTD |
|---|---|---|
| P/E Ratio (TTM) | 69.46 | 37.38 |
| P/S Ratio (TTM) | 3.19 | 8.16 |
| P/B Ratio (MRQ) | 3.59 | 442.71 |
| Free Cash Flow Yield (TTM) | 11.16% | 1.97% |